Abbott Laboratories (ABT) announced its first-quarter 2019 earnings results on Wednesday, April 17, before the opening bell.
In the three-month period, worldwide sales grew 2% to $7.5 billion, with earnings from continuing operations jumping 65% to 38 cents per diluted share. Adjusted diluted EPS from continuing operations improved by 6.3% to $0.63.
Total net earnings jumped 61% year-over-year to $672 million.
Back in January, Abbott also received the FDA approval for a “new, expanded indication” for its MitraClip device to treat clinically significant secondary mitral regurgitation — a leaky heart valve resulting from advanced heart failure.
Then in March, Abbott obtained the CE Mark for its Alinity (molecular) diagnostics system and testing assays to aid in infectious disease testing.
“We’re right on track with our expectations to start the year,” said Abbott CEO Miles D. White, “…all of our key long-term growth drivers are performing well and we’re targeting another year of strong sales and earnings growth.”
Abbott now projects full-year 2019 GAAP earnings to be between $1.95 to $2.05 per diluted share, and adjusted diluted earnings from continuing operations to be $3.15-3.25 per share for the same period.
For the second quarter of 2019, Abbott sees GAAP diluted EPS of $0.47-0.49, and projects adjusted diluted earnings from continuing operations of $0.79-0.81 per share.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
Target (TGT): A look at some of the challenges faced by the retailer in 3Q24
Shares of Target Corporation (NYSE: TGT) stayed green on Thursday, recovering from the stumble it took a day ago after delivering disappointing results for the third quarter of 2024 and